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or DCIS [5], and ADH lesions frequently 
coexist with DCIS or invasive carcinoma 
[6]. For these reasons, lesions determined 
to be ADH at core needle biopsy often are 
found to be malignant tumors at subsequent 
surgery [7, 8]. Reports [9–16] indicate a 
20–56% rate of underestimation of ADH at 
stereotactic 14-gauge automated core biopsy 
and a 11–27% rate at stereotactic 11-gauge 
vacuum-assisted biopsy. Because most 
lesions containing ADH have calcifications, 
underestimation at percutaneous biopsy is 
most common for calcific lesions examined 
with stereotactic biopsy [17]. Few reports 
have addressed the rate of underestimation 
of ADH and factors affecting this rate at 
sonographically guided core biopsy [18–21]. 
The purpose of this study was to determine 
the rate of underestimation of ADH at 
sonographically guided core biopsy of the 
breast and to identify the factors involved.
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S
onographically guided per cu ta-
neous biopsy of the breast is an 
established alternative to surgical 
excision. The advantages of so-
nog raphy as a guidance technique include 
lack of ionizing radiation, use of nondedicated 
equipment, and real-time visualization of the 
biopsy needle. For lesions amenable to stereo-
tactic and sonographically guided biop sy, 
sonographically guided biopsy is pref er able 
in terms of patient comfort, procedure time, 
and cost [1–3].
Atypical ductal hyperplasia (ADH) is the 
most common high-risk lesion of the breast. 
It is defined as a ductal hyperplastic lesion 
that has cellular atypia and structural rigidity 
suggesting ductal carcinoma in situ (DCIS) 
but involving only one duct profile or an area 
less than 2 mm in diameter [4]. Pathologists 
have considerable interobserver variability in 
terms of determining whether a lesion is ADH 
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W O M E N ’ S
I M A G I N G
OBJECTIVE. The purpose of this study was to determine the rate of underestimation of 
atypical ductal hyperplasia (ADH) at sonographically guided core biopsy of the breast and to 
identify the factors involved.
MATERIALS AND METHODS. We retrospectively reviewed 3,563 lesions con sec-
utively evaluated with sonographically guided core biopsy between January 2002 and 
June 2006. Histologic analysis yielded ADH in 60 of the 3,563 lesions (1.7%). The rate of 
underestimation of ADH was determined by dividing the number of lesions that proved to be 
carcinoma at surgical excision by 44, the total number of lesions evaluated with excisional 
biopsy. Clinical, sonographic, and core biopsy features were analyzed to identify factors that 
affect the rate of underestimation of ADH.
RESULTS. The rate of underestimation of ADH was found to be 48% (21 of 44 lesions). 
Underestimation of ADH was significantly less frequent for lesions evaluated with 11-gauge 
vacuum-assisted biopsy than for lesions evaluated with 14-gauge automated gun biopsy (22% 
[four of 18 lesions] vs 65% [17 of 26 lesions], p = 0.012). The other clinical, sonographic, and 
biopsy features examined did not affect the rate of underestimation of ADH.
CONCLUSION. For sonographically guided core biopsy of the breast, the rate of 
underestimation of ADH was 48%. This rate was lower for lesions evaluated with 11-gauge 
vacuum-assisted biopsy (22%) than for those evaluated with 14-gauge automated gun biopsy 










We retrospectively evaluated the results of 
sonographically guided core needle biopsy of 
3,563 consecutively detected breast lesions in 
3,377 consecutively registered patients (mean 
age, 45.2 years; range, 17–87 years) who were 
examined between January 2002 and June 2006 
at our institution. Of these 3,377 women, 3,202 
underwent biopsy for one lesion, 164 women for 
two separate lesions, and 11 for three separate 
lesions. Referring physicians reported that 655 of 
the 3,563 lesions (18.4%) were palpable. Medical 
records were reviewed to obtain patient ages, 
personal medical histories, and family histories of 
breast cancer.
Sonographically guided percutaneous biopsy 
yielded benign histologic findings on 2,534 of 
the 3,563 lesions (71%), high-risk findings on 
252 lesions (7%), and malignant findings on 777 
lesions (22%). Biopsy of 60 of the 3,563 lesions 
(1.7%) yielded a finding of ADH. Among the 60 
women with these lesions, seven women were lost 
to follow-up, and nine women underwent one or 
two follow-up imaging examinations 6–32 months 
after detection without undergoing surgery. No 
malignancy was found in the follow-up group. 
Forty-four women with 44 lesions (26 who 
underwent 14-gauge automated gun biopsy, 18 
who underwent 11-gauge vacuum-assisted biopsy) 
who underwent surgical excision constituted the 
study group. This study was approved by the 
institutional review board, which waived the 
requirement for informed consent.
Biopsy Procedure
All biopsies were guided by high-resolution 
sonography performed with a unit equipped with 
a 10- or 12-MHz linear transducer (Voluson 730, 
GE-Kretz; HDI 5000, Advanced Technology 
Laboratories). Patients were in the supine or 
oblique supine position. A 14-gauge automated 
gun (Pro-Mag 2.2, Manan Medical Products) 
was used on 2,463 lesions (69%) and an 11-gauge 
vacuum-assisted device (Mammotome, Ethicon 
Endo-Surgery) on 1,100 lesions (31%) (Table 1).
Radiologists performing biopsies were pri-
marily responsible for choosing the biopsy device 
used. Automated gun biopsy was preferred for 
multifocal lesions and for lesions in the subareolar 
or axillary area. The 11-gauge vacuum-assisted 
device was preferred for intraductal lesions and 
solid nodules smaller than 10 mm in diameter. 
When automated gun biopsy was used, needle 
insertion was immediately proximal to the lesion. 
After the lesion capsule was pierced, the gun was 
fired into the lesion for automatic sampling of a 
small core. After the device was fired, longitudinal 
and transverse images of needles located in the 
center of the mass were obtained. Our protocol 
required that at least four nonfragmented samples 
be obtained with the automated gun biopsy. When 
a vacuum-assisted biopsy device was used, a 
small skin incision was made, and the needle 
was inserted either through or directly subjacent 
to the lesion. The needle was manually rotated in 
a circumferential clockwise manner for sampling 
of both the target lesion and adjacent tissues. Our 
protocol required removal of all evidence of the 
target lesion during vacuum-assisted biopsy.
An average of five core samples (range, three to 
eight) was obtained with the 14-gauge automated 
gun and 14 (range, seven to 33) with the 11-gauge 
vacuum-assisted device. Approximately 20% of 
biopsies were performed by one of two attending 
radiologists with 4–7 years of experience in breast 
sonography and intervention. The other biopsies 
were performed by one of four fellows, who 
performed their first five to 10 biopsies under the 
supervision of an attending radiologist.
Assessment of Variables
Lesion variables, including size (maximal 
diameter on sonograms), type (mass with 
calcifications or mass only according to mammo-
graphic findings), and BI-RADS final assessment 
category, were determined by two radiologists in 
consensus before biopsy. According to the prob-
ability of malignancy, subcategories of category 
4 were described as 3–10% in 4a (low level of 
suspicion), 11–50% in 4b (intermediate suspicion), 
and 51–94% in 4c (moderate suspicion). Biopsy 
variables including the biopsy method used and 
number of core specimens retrieved were recorded 
during biopsy procedures. Histologic results of core 
biopsy were compared with those obtained during 
subsequent surgery. Coexistent pathologic lesions 
and the presence of a second high-risk lesion 
associated with ADH were evaluated by review of 
histology reports at final excision.
Postbiopsy Management
Patients with a biopsy result of malignancy 
(invasive ductal carcinoma, DCIS, invasive 
lobular carcinoma, or malignant phyllodes tumor) 
underwent surgical excision. Surgical excision was 
recommended for patients with a high-risk lesion 
(ADH, atypical papillary tumor, radial scar, benign 
phyllodes tumor, atypical lobular hyperplasia, 
lobular carcinoma in situ, or a mucocele-like 
tumor). When a lesion with a benign pathologic 
result (all lesions not malignant or high-risk lesions) 
was determined to have concordant imaging 
findings, 6-, 12-, and 24-month follow-up imaging 
examinations were recommended. If a lesion with 
a benign pathologic result had a highly suspicious 
sonographic finding, surgical excision was 
recommended despite the benign pathologic result.
Data Analysis
Underestimation of ADH was defined as having 
occurred when the finding of ADH at core biopsy 
was changed to carcinoma (DCIS or invasive ductal 
carcinoma) at surgery. The rate of underestimation 
of ADH was determined by dividing the number 
of lesions proved DCIS or invasive carcinoma 
at excision by the total number of lesions for 
which excisional biopsy was performed. We also 
evaluated whether underestimation of ADH was 
affected by a family or personal history of breast 
cancer, lesion size, lesion type, final assessment 
category, biopsy method, number of core 
specimens, and the presence of a high-risk lesion 
in the surgical specimen. To identify factors that 
affected underestimation of ADH, we compared 
the rates of underestimation of lesions with and 
without factors related to lesion characteristics. 
Analysis was performed with the chi-square test, 




Gun (n = 2,463)
11-Gauge Vacuum-Assisted 
Device (n = 1,100) p
Histologic diagnosis
Malignant lesion 595 182
High-risk lesion 138 114
Benign lesion 1,730 804
Case inclusion
ADH lesion 28 (1.1) 32 (2.9) < 0.001
ADH lesions managed with surgery 26 18
ADH with subsequent malignancy found 17 4
Rate of underestimation of ADH 17/26 (65) 4/18 (22) 0.012
Note—Values in parentheses are percentages. ADH = atypical ductal hyperplasia.
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Fisher’s exact test, and Student’s t test in the SPSS 
program (version 10.0 for Microsoft Windows, 
SPSS). Values of p < 0.05 were considered to 
indicate a significant difference.
Results
The prevalence of ADH at sonographically 
guided biopsy was 1.7% (60 of 3,563 lesions). 
Of the 60 lesions, 28 were detected with 
14-gauge automated gun biopsy (1.1% of 
2,463 lesions biopsied with this technique) 
and 32 with 11-gauge vacuum-assisted 
biopsy (2.9% of 1,100 biopsied with this 
technique) (p < 0.001). Forty-four lesions 
were surgically excised, and 21 of these 
lesions proved to be carcinoma (12 DCIS, 
nine invasive ductal carcinomas) (Table 1), 
an ADH underestimation rate of 48% (21 of 
44 lesions).
Table 2 compares the accurate diagnoses 
(n = 23) and underestimations (n = 21) 
according to patient, lesion, and biopsy 
variables. Women in the accurate diagnosis 
group were younger than those in the 
underestimation group (mean age, 46 vs 52 
years; p = 0.016). Seventeen of the 26 ADH 
lesions (65%) found with 14-gauge automated 
gun biopsy were upgraded to carcinoma (10 
DCIS, seven invasive ductal carcinomas), 
and four of the 18 ADH lesions (22%) found 
with 11-gauge vacuum-assisted biopsy were 
upgraded to carcinoma (two DCIS, two invasive 
ductal carcinomas). The underestimation rate 
for 11-gauge vacuum-assisted biopsy (22%) 
was significantly lower than that for 14-gauge 
automated gun biopsy (65%) (p = 0.012).
No difference was found between the 
accurate diagnosis and underestimation 
groups in terms of family or personal 
history of breast cancer (p = 1.0), lesion 
size (p = 0.272), lesion type (p = 0.761), 
BI-RADS category (p = 0.559), number of 
core specimens (p = 0.108), or presence of 
combined high-risk lesions (p = 0.526). The 
accurate diagnosis group had three papillary 
lesions, one radial scar, and two mucocele-
like lesions; the underestimation group had 
four papillary lesions, one radial scar, and 
one lobular carcinoma in situ.
The underestimation rates for 14-gauge 
automated gun biopsy and 11-gauge vacuum-
assisted biopsy were compared with respect 
to lesion characteristics (Table 3). The rate 
of underestimation of ADH at 14-gauge 
automated gun biopsy was higher than that 
of 11-gauge vacuum-assisted biopsy for 
smaller (≤ 2.0 cm) lesions (61% [14 of 23 
lesions] versus 8% [one of 12], p = 0.004)] 
and mass-only lesions (67% [14 of 21] versus 
0% (zero of seven), p = 0.009). No difference 
was observed between the underestimation 
rates of the two biopsy methods for larger 
(≥ 2.1 cm) lesions (p = 0.464) or masses with 
calcification (p = 0.734). There also were no 
differences related to BI-RADS category.
Discussion
In this study, the rate of underestimation of 
ADH at sonographically guided core biopsy 
was found to be 48% (21 of 44 lesions) 
among 3,563 consecutive sonographically 
guided core needle biopsies of the breast. 
Our rate of underestimation of ADH with 
sonographically guided biopsy concurs with 
those in previous reports of stereotactic 
biopsy: a 20–56% rate of underestimation of 
ADH with 14-gauge automated gun biopsy 
and an 11–27% rate with 11-gauge vacuum-
assisted biopsy [9–12]. However, the clinical 
significance of underestimation of ADH with 
sonographically guided biopsy is much lower 
than that of stereotactic biopsy. Whereas 
a 4–7% prevalence of ADH at stereotactic 
biopsy has been reported [9–16], in our 
study, the prevalence of ADH was only 1.7% 
(60 of 3,563 lesions) with sonographically 
guided biopsy. Our finding concurs with the 
ADH prevalences of 0.4–2.5% previously 
reported for sonographically guided biopsy 
[18–21]. Prevalence of ADH determined with 
percutaneous biopsy depends on lesion type; 
that is, the prevalence of ADH increases 





(n = 21) p
Mean ± SD patient age (y) 46 ± 9.4 52 ± 8.3 0.016
Family or personal history of breast cancer 1.0
Present 4 4
Absent 19 17
Mean ± SD lesion size (cm) 1.3 ± 0.7 1.6 ± 1.0 0.394
Lesion size 0.272
≤ 2.0 20 15
≥ 2.1 3 6
Lesion type 0.761
Mass with calcifications 9 7








14-gauge automated gun 9 17
11-gauge vacuum assisted 14 4
No. of specimens 0.108
≤ 5 5 11
6–10 11 6
≥ 11 7 4





Note—ADH = atypical ductal hyperplasia.
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when more lesions with calcifications are 
included [16]. However, lesions manifesting 
as calcifications alone are rarely encountered 
at sonography; thus the prevalence of ADH is 
minimal as determined with sonographically 
guided biopsy.
The outcome of percutaneous biopsy of 
the breast depends mainly on lesion type 
and the amount of sample obtained. In this 
study, use of an 11-gauge vacuum-assisted 
device was associated with a lower rate of 
underestimation of ADH compared with 
14-gauge core biopsy. This finding was 
notable for small lesions (≤ 2.0 cm) (8% 
[one of 12 lesions] vs 61% [14 of 23], p = 
0.004) and for mass-only lesions (0% [zero 
of seven lesions] vs 67% [14 of 21], p = 
0.009). Many studies [9–12] of stereotactic 
biopsy have shown that 11-gauge vacuum-
assisted devices remove larger amounts of 
tissue than do 14-gauge core biopsy devices 
and that use of 11-gauge devices is associated 
with a lower rate of underestimation of 
ADH. These findings may be applicable 
to sonographically guided biopsy. Calcific 
lesions, in which ADH is commonly found, 
have a heterogeneous and discontinuous 
distribution; thus larger sample volumes 
are needed than for mass lesions [17, 22]. In 
one stereotactic biopsy series [23], the rate 
of underestimation of ADH was higher for 
masses than for microcalcifications. Our 
results, however, suggest that use of 11-gauge 
vacuum-assisted biopsy reduces the rate of 
underestimation of masses alone but not of 
masses with calcifications at sonographically 
guided biopsy. Because calcifications are 
barely visible at sonography, calcifications 
remaining after biopsy were thought be the 
cause of underestimation.
The partial volume averaging effect is a 
well-known cause of inadequate targeting 
during sonographically guided biopsy, notably 
of small lesions. With vacuum-assisted 
devices, samples can be contiguous and larger 
than with the 14-gauge gun, and all evidence 
of lesions can be removed. These features 
overcome the partial volume averaging effect 
of small lesions and min i mize the residual 
lesions that cause histo logic underestimation. 
Sonographically guided vacuum-assisted 
removal of all sonographic evidence of a 
lesion was associated with a 0% (zero of 29 
lesions) rate of underestimation of ADH in 
one study [19]. Even complete removal of 
all mammographic evidence at stereotactic 
11-gauge vacuum-assisted biopsy, however, 
revealed residual lesion during surgical 
excision [24] and had an 8% (three of 36 
lesions) rate of underestimation of ADH [16].
Although reduced underestimation with 
use of an 11-gauge vacuum-assisted device 
is explained by larger sample volumes, there 
is a tendency to obtain more cores for larger 
lesions or lesions that are difficult to target. 
Thus the number of specimens obtained 
appears not to be correlated with a lower rate 
of underestimation (Table 2). These results 
are similar to those of a previous study 
[16], in which the investigators found that 
specimen numbers per lesion did not correlate 
with underestimation but that complete 
lesion removal did correlate with degree of 
underestimation. These findings indicate 
that targeting precision is more important 
than sample numbers. Further studies with 
more cases are needed to determine whether 
complete lesion removal at sonographically 
guided 11-gauge vacuum-assisted biopsy can 
reduce the rate of underestimation of ADH.
We also evaluated whether finding a 
second high-risk lesion at core biopsy was 
related to rate of underestimation of ADH, 
hoping to find a histologic feature at core 
biopsy that could serve as a marker for 
high risk. We found no difference between 
the accurate diagnosis and underestimation 
groups in terms of presence of a second high-
risk lesion at core biopsy (Table 2).
Our study had several limitations. First, 
biopsies were performed by one of six 
radiologists with different levels of ex pe ri-
ence. Although the first five to 10 biopsies 
by fellows were performed under the 
supervision of an attending radiologist, the 
training process, especially concerning ac-
cu rate targeting, might have been in-
complete. Second, decisions concerning the 
biopsy device used were not randomized. 
A 14-gauge automated gun was preferred 
for multifocal lesions and for lesions in the 
subareolar or axillary area, and an 11-gauge 
vacuum-assisted device was preferred 
for intraductal lesions and solid nodules 
smaller than 10 mm, for which the potential 
benefits of use of the vacuum-assisted device 
had already been suggested. Third, our 
biopsy protocols involved removal of all 
evidence of lesions targeted during 11-gauge 
vacuum-assisted biopsy and acquisition of 
at least four nonfragmented samples during 
14-gauge automated gun biopsy, and these 
factors might have affected the rate of 
underestimation of ADH.
For sonographically guided core biopsy 
of the breast, the rate of underestimation of 
ADH was found to be 48%. This rate was 
lower for 11-gauge vacuum-assisted biopsy 
(22%) than for 14-gauge automated gun 
biopsy (65%), notably for lesions 20 mm 
or smaller and for lesions of the mass-only 
type. These findings, however, do not mean 
that we prefer vacuum-assisted biopsy to 
automated gun biopsy for all sonographic 
TABLE 3: Rates of Underestimation of Atypical Ductal Hyperplasia for 
14-Gauge Automated Gun and 11-Gauge Vacuum-Assisted Biopsies 







(n = 18) Total p
Lesion size (cm)
≤ 2.0 14/23 (61) 1/12 (8) 15/35 (43) 0.004




3/5 (60) 4/11 (36) 7/16 (44) 0.734
Mass only 14/21 (67) 0/7 (0) 14/28 (50) 0.009
BI-RADS category
3 1/2 (50) 0 1/2 (50)
4a 7/13 (54) 3/11 (27) 10/24 (42) 0.240
4b 6/8 (75) 1/5 (20) 7/13 ( 54) 0.103
4c 1/1 (100) 0/2 (0) 1/3 (33)
5 2/2 (100) 0 2/2 (100)
Note—Values in parentheses are percentages.
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lesions in clinical practice. The decision 
about which biopsy method to use also 
depends on procedure-related complications, 
cost-effectiveness, and time.
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